### FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
OMB Number: 3235-02										
	Estimated average burden									
l	hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Mortenson Mark					2. Issuer Name and Ticker or Trading Symbol Clene Inc. [ CLNN ]					5. Reli (Chec	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner						
(Last) 6550 SO	t) (First) (Middle) 0 SOUTH MILLROCK DRIVE				3. Date of Earliest Transaction (Month/Day/Year) 06/07/2024						V	Officer (give title Other (specify below)  Chief Science Officer					
SUITE G50					4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person						
(Street) SALT LAKE CITY  84121				Rule 10b5-1(c) Transaction Indication													
(City) (State) (Zip)				Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					action 2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. ) 8)  4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4)		red (A) or str. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Foll Reported		Form:	Direct I Indirect I tr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code V	Amoun	(A) or (D) Price		Transaction(s) (Instr. 3 and 4)			l(ir	msu. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, Tra ecurity or Exercise (Month/Day/Year) if any Co		Transa Code	5. Number Derivative Securities Acquired (or Dispose (D) (Instr. 3 and 5)			Expiration Date (Month/Day/Year) A) d of		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s		10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	1011(3)			
Stock Options (Right to buy)	\$0.37	06/07/2024		A		2,000,000		(1)	06/06/2034	Common Stock	2,000,000	\$0.00	2,000,0	000	D		
Stock Options (Right to buy)	\$0.37	06/07/2024		A		800,000		(2)	06/06/2034	Common Stock	800,000	\$0.00	800,00	00	D		

### **Explanation of Responses:**

- 1. This option was granted on June 7, 2024 as an option for 2,000,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of \$0.37 per share. The options vest with respect to the first 33.3% of such shares if Clene Inc. has an NDA accepted by the FDA, an additional 33.3% of such shares if Clene Inc. has an NDA approved by the FDA, and the remaining 33.4% of such shares if Clene Inc. achieves \$100,000,000 in revenues in connection with the sales of any approved drugs.
- 2. This option was granted on June 7, 2024 as an option for 800,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of \$0.37 per share. The options vest with respect to the first 25% of such shares on June 7, 2025 and then in 36 equal installments of Common Stock on the 7th day of each calendar month, beginning July 7, 2025, until such shares are fully vested

## Remarks:

/s/ Jerry Miraglia POA

06/10/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.